APA (7th ed.) Citation

Minckwitz, G. v., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., . . . Untch, M. (2014). Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. The lancet. Oncology, 15(7), . https://doi.org/10.1016/S1470-2045(14)70160-3

Chicago Style (17th ed.) Citation

Minckwitz, Gunter von, et al. "Neoadjuvant Carboplatin in Patients with Triple-negative and HER2-positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial." The Lancet. Oncology 15, no. 7 (2014). https://doi.org/10.1016/S1470-2045(14)70160-3.

MLA (9th ed.) Citation

Minckwitz, Gunter von, et al. "Neoadjuvant Carboplatin in Patients with Triple-negative and HER2-positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial." The Lancet. Oncology, vol. 15, no. 7, 2014, https://doi.org/10.1016/S1470-2045(14)70160-3.